Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide-induced arthritis in rabbits

Inflammation Research

Volumn 45, Issue 9, 1996, Pages 479-485

  Fukumoto, T ^a   Matsukawa, A ^a   Ohkawara, S ^a   Takagi, K ^a   Yoshinaga, M ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Anti IL 1ra monoclonal antibody; IL 1; IL 1 receptor antagonist; Lipopolysaccharide induced arthritis

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; FEMALE; KNEE; LEUKOCYTE; NONHUMAN; RABBIT; SYNOVIAL FLUID;

EID: 0029795485     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02252320     Document Type: Article

References (40)

1. di Giovine FS, Duff GW. Interleukin 1: the first interleukin. Immunol Today 1990;11:13-20.
2. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989;44:153-205.
3. Dinarello CA. The biology of interleukin-1. Chem Immunol 1992;51:1-32.
4. Dinarello CA. Modalities for reducing interleukin 1 activity in disease. Immunol Today 1993;14:260-4.
5. Carter DB, Deibel MJ, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8.
6. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6.
7. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
8. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991;12:404-10.
9. Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
10. Lebsack ME, Paul CC, Martindale MA. A dose- and regimen-ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthr Rheum 1993;36:S39.
11. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342-8.
12. Matsukawa A, Ohkawara S, Maeda T, Takagi K, Yoshinaga M. Production of IL-1 and IL-1 receptor antagonist and the pathological significance in lipopolysaccharide-induced arthritis in rabbits. Clin Exp Immunol 1993;93:206-11.
13. Matsukawa A, Furukawa S, Ohkawara S, Takagi K, Yoshinaga M. Development of a neutralizing monoclonal antibody against rabbit IL-1 receptor antagonist and utilization for ELISA and measurement of masked IL-1 activity in biological materials. Immunol Invest 1994;23:129-42.
14. Chikanza IC, Roux LP, Dayer JM, Panayi GS. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthr Rheum 1995;38:642-8.
15. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993;341:146-8.
16. Casini RV, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-40.
17. Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science 1960;132:1770-1.
18. Matsukawa A, Mori S, Ohkawara S, Maeda T, Tanase S, Edamitsu S, et al. Production, purification and characterization of a rabbit recombinant IL-1 receptor antagonist. Biomed Res 1992;13:269-77.
19. Goto F, Goto K, Mori S, Ohkawara S, Yoshinaga M. Biosynthesis of interleukin-1β at inflammatory site in rabbits: kinetics and producing cells. Br J Exp Pathol 1989;70:597-606.
20. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Meth 1984; 68:167-75.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
22. Goto F, Goto K, Miyata T, Ohkawara S, Takao T, Mori S, et al. Interleukin-1 receptor antagonist in inflammatory exudate cells of rabbits. Production, purification and determination of primary structure. Immunology 1992;77:235-44.
23. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991;266:10331-6.
24. Dripps DJ, Verderber E, Ng RK, Thompson RC, Eisenberg SP. Interleukin-1 receptor antagonist binds to the type II interleukin-1 receptor on B cells and neutrophils. J Biol Chem 1991;266:20311-5.
25. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991;266:14147-50.
26. Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987;139:1902-10.
27. Chensue SW, Bienkowski M, Eessalu TE, Warmington KS, Hershey SD, Lukacs NW, et al. Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response. J Immunol 1993;151:3654-62.
28. Ferretti M, Casini RV, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994;94:449-53.
29. Fujioka N, Mukaida N, Harada A, Akiyama M, Kasahara T, Kuno K, et al. Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice. J Leukoc Biol 1995;58:90-8.
30. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthr Rheum 1994;37:644-52.
31. Chomarat P, Vannier E, Dechanet J, Rissoan MC, Banchereau J, Dinarello CA, et al. Balance of IL-1 receptor antagonist IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
32. Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 1973;16:265-336.
33. Chantry D, Winearls CG, Maini RN, Feldmann M. Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-γ and tumor necrosis factor-α. Eur J Immunol 1989;19:189-92.
34. Marsh CB, Gadek JE, Kindt GC, Moore SA, Wewers MD. Monocyte Fcγ receptor cross-linkine induces IL-8 production. J Immunol 1995;155:3161-7.
35. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-5.
36. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today 1994;15:562-6.
37. Bristulf J, Bartfai T. Interleukin-1β and tumour necrosis factor-α stimulate the mRNA expression of interleukin-1 receptors in mouse anterior pituitary AtT-20 cells. Neurosci Lett 1995;187:53-6.
38. Haranaka K, Satomi N, Sakurai A, Nariuchi H. Purification and partial amino acid sequence of rabbit tumor necrosis factor. Int J Cancer 1985;36:395-400.
39. Ikejima T, Okusawa S, Ghezzi P, van der Meer JWM, Dinarello CA. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J Infect Dis 1990;162:215-23
40. Marsh CB, Moore SA, Pope HA, Wewers MD. IL-1ra suppresses endotoxin-induced IL-1β and TNF-α release from mononuclear phagocytes. Am J Physiol 1994;267:L39-45.